XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syn…
| Métrica | XTLB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 0.7% | 57.4% | -56.7% |
| Operating Margin | -481.6% | -34.4% | -447.2% |
| Net Margin | -227.7% | -32.5% | -195.3% |
| FCF Margin | -370.7% | -12.6% | -358.1% |
| ROE | -18.9% | -39.2% | +20.3% |
| ROA | -12.0% | -30.9% | +18.9% |
| Current Ratio | 0.61 | 2.73 | -2.12 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -12.0% | — |
| ✗Flujo de caja operativo positivo | −$2M | −$707,000 |
| ✓Rentabilidad sobre activos al alza | -12.0% | -73.5% |
| ✗Caja operativa/activos supera al ROA | -18.9% | ROA -12.0% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 0.61 | 9.93 |
| ✗Sin aumentar el nº de acciones | 704M | 545M |
| –Margen bruto al alza | 0.7% | — |
| –Rotación de activos al alza | 0.05 | — |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -370.7% |
| ✗ROCE > 10 % | -34.2% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 33.7% |
XTL BIOPHARMACEUTICALS LTD cotiza a 1.96 USD y tiene una capitalización bursátil de $5M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud